What we learned from Biotech YC applications
Aggregate insights from real applications roasted on YC Roaster — the patterns YC partners look for, and the weaknesses that come up over and over.
Apps analyzed
19
Average score
3.85 /5
Updated
Jun 15, 2026
Score breakdown — Biotech average
Biggest weaknesses
Where Biotech applications consistently fall short.
- 1. Early Traction3.27/5
- 2. Monetization3.53/5
- 3. GTM3.56/5
Strongest dimensions
Where Biotech applications tend to do well.
- 1. App Completeness4.32/5
- 2. Market4.17/5
- 3. Team Quality4.09/5
Score distribution
What our AI judge actually said
Anonymized critique from real Biotech applications (shared with founder consent).
“Eight months full time with zero revenue, just $5 activation fees from four labs, no proof pilots convert to paid.”
7.3/10·Smart team with rare insight on frontier research, but traction is all pilots, no revenue proof.
“June for a deployable prototype is late when one founder is part-time until July and you have zero users.”
6.9/10·Strong problem and wedge, but execution velocity is too slow to matter without dramatic acceleration.
“You have 8 pilots and 100% say they'll pay, but your revenue is still zero, willingness to pay is not a business model.”
8.0/10·Rare founder-market fit and fast execution, but you need 10 paying customers to prove this scales beyond pilots.
“Zero revenue after 8 months and pilots that need founder calls means this might be consulting dressed up as software, not a scalable product yet”
7.8/10·Real product, real researchers want it, strong team, but prove pilots convert to cash and self-service actually works without you
See where your Biotech app stacks up
Get a YC-partner-style scorecard on your application in 72 hours. Free.
Get your free roast →